Multicentre international trial of laparoscopic lavage for Hinchey III acute diverticulitis (LLO Study). BJS 2018; 105: 1835-1843.
Published: 14th July 2018
Authors: G. A. Binda, M. A. Bonino, G. Siri, S. Di Saverio, G. Rossi, R. Nascimbeni et al.
Laparoscopic lavage was proposed in the 1990s to treat purulent peritonitis in patients with perforated acute diverticulitis. Prospective randomized trials had mixed results. The aim of this study was to determine the success rate of laparoscopic lavage in sepsis control and to identify a group of patients that could potentially benefit from this treatment.
This retrospective multicentre international study included consecutive patients from 24 centres who underwent laparoscopic lavage from 2005 to 2015.
A total of 404 patients were included, 231 of whom had Hinchey III acute diverticulitis. Sepsis control was achieved in 172 patients (74·5 per cent), and was associated with lower Mannheim Peritonitis Index score and ASA grade, no evidence of free perforation, absence of extensive adhesiolysis and previous episodes of diverticulitis. The operation was immediately converted to open surgery in 19 patients. Among 212 patients who underwent laparoscopic lavage, the morbidity rate was 33·0 per cent; the reoperation rate was 13·7 per cent and the 30‐day mortality rate 1·9 per cent. Twenty‐one patients required readmission for early complications, of whom 11 underwent further surgery and one died. Of the 172 patients discharged uneventfully after laparoscopic lavage, a recurrent episode of acute diverticulitis was registered in 46 (26·7 per cent), at a mean of 11 (range 2–108) months. Relapse was associated with younger age, female sex and previous episodes of acute diverticulitis.
Laparoscopic lavage showed a high rate of successful sepsis control in selected patients with perforated Hinchey III acute diverticulitis affected by peritonitis, with low rates of operative mortality, reoperation and stoma formation.Full text
You may also be interested in
Impact of enhanced recovery on oncological outcomes following minimally invasive surgery for rectal cancer.
Authors: B. J. Quiram, J. Crippa, F. Grass, J. K. Lovely, K. T. Behm, D. T. Colibaseanu et al.
Multicentre study of non‐surgical management of diverticulitis with abscess formation. BJS 2019; 106: 458-466.
Authors: D. P. V. Lambrichts, H. E. Bolkenstein, D. C. H. E. van der Does, D. Dieleman, R. M. P. H. Crolla, J. W. T. Dekker et al.
Randomized clinical trial
Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial). BJS 2019; 106: 355-363.
Authors: G. S. A. Abis, H. B. A. C. Stockmann, H. J. Bonjer, N. van Veenendaal, M. L. M. van Doorn‐Schepens, A. E. Budding et al.
Population‐based study of surgical treatment with and without tumour resection in patients with locally recurrent rectal cancer.
Authors: K. Westberg, G. Palmer, F. Hjern, T. Holm, A. Martling
Patient‐reported functional and quality‐of‐life outcomes after transanal total mesorectal excision. BJS 2019; 106: 364-366.
Authors: D. S. Keller, C. Reali, A. Spinelli, M. Penna, F. Di Candido, C. Cunningham et al.
Authors: C. F. Justiniano, Z. Xu, A. Z. Becerra, C. T. Aquina, C. I. Boodry, L. K. Temple et al.
Functional outcomes from a randomized trial of early closure of temporary ileostomy after rectal excision for cancer.
Authors: C. Keane, J. Park, S. Öberg, A. Wedin, D. Bock, G. O'Grady et al.
Long‐term functional outcomes and quality of life in patients with Hirschsprung’s disease. BJS 2019; 106: 499-507.
Authors: R. J. Meinds, A. F. W. van der Steeg, C. E. J. Sloots, M. J. Witvliet, I. de Blaauw, W. G. van Gemert et al.
Influence of the level of sacrectomy on survival in patients with locally advanced and recurrent rectal cancer. BJS 2019; 106: 484-490.
Authors: Y. C. Lau, K. Jongerius, C. Wakeman, A. G. Heriot, M. J. Solomon, P. M. Sagar et al.
Cost‐effectiveness analysis of a multicentre randomized clinical trial comparing surgery with conservative management for recurrent and ongoing diverticulitis (DIRECT trial). BJS 2019; 106: 448-457.
Authors: H. E. Bolkenstein, G. A. de Wit, E. C. J. Consten, B. J. M. Van de Wall, I. A. M. J. Broeders, W. A. Draaisma et al.
Notes: Maintained benefits
Sex differences in faecal occult blood test screening for colorectal cancer. BJS 2019; 106: 436-447.
Authors: L. Koskenvuo, N. Malila, J. Pitkäniemi, J. Miettinen, S. Heikkinen, V. Sallinen et al.
Notes: Only of benefit in men
Diffusion‐weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. BJS 2019; 106: 491-498.
Authors: I. van 't Sant, W. J. van Eden, M. P. Engbersen, N. F. M. Kok, K. Woensdregt, D. M. J. Lambregts et al.
Notes: Promising staging tool